Referencias acerca de GARDASIL® [Vacuna Cuadrivalente contra el Virus del Papiloma Humano (Tipos 6, 11, 16, 18 del VPH), Recombinante]

1.	American Cancer Society. Cervical cancer. Available at: http://documents.cancer.org/115.00/115.00.pdf. Accessed June 12, 2006.
2.	Centers for Disease Control and Prevention. Genital HPV infection fact sheet. Available at: http://www.cdc.gov/std/hpv/stdfact-hpv.htm. Accessed June 12, 2006.
3.	Lacey JN. Therapy for genital human papillomavirus-related disease. J Clin Virol. 2004;32(Suppl):S82–S90.
4.	National Institute of Allergy and Infectious Diseases. Human papillomavirus and genital warts. July 2004. Available at: http://www.niaid.nih.gov/factsheets/stdhpv.htm. Accessed June 12, 2006.
5.	Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspectives on Sexual Reproductive Health. 2004;36:6–10.
6.	Winer RL, Lee S-K, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157:218–226.


	Página fácil de imprimir

Esta página es sólo para residentes de los Estados Unidos, sus territorios y Puerto Rico. GARDASIL es una marca registrada de Merck & Co., Inc.